FRAMINGHAM, Mass. and SYDNEY, Nov. 6 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) a leading innovator and provider of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that it is scheduled to make presentations at two upcoming investor conferences in November.
The first presentation will be made at the Third Annual Canaccord Adams Cardiovascular Conference at 9:00 am PST on Tuesday, November 10. The one-day conference will be held at the Nikko Hotel in San Francisco.
The second presentation will be made at the Lazard Capital Markets Sixth Annual Healthcare Conference at 10:30 am EST on Wednesday, November 18. The conference will be held at the St. Regis Hotel in New York City, November 17-18.
Live webcasts of the Company's presentations at the conferences will be available via a link provided at www.heartware.com. Archived replays of the presentations will also be available shortly after the presentation time for a period of at least 60 days.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or left ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare® Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.
For further information: US Investor Relations Matt Clawson Partner Allen & Caron Inc Email: firstname.lastname@example.org Tel: +1 949 474 4300
SOURCE HeartWare International, Inc.
|SOURCE HeartWare International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved